Comparing Day 3 and Day 5 Embryo Transfer Timing in Women Undergoing IVF with Few Embryos
Led by Beth Israel Deaconess Medical Center · Updated on 2026-04-02
1126
Participants Needed
1
Research Sites
30 weeks
Total Duration
AI-Summary
What this Trial Is About
Infertility affects over 6 million women in the United States and brings various emotional, physical, and financial challenges. This research aims to compare pregnancy outcomes and patient satisfaction between two embryo transfer timings in IVF patients who have five or fewer embryos. The study focuses on helping patients and providers make evidence-based decisions on when to transfer embryos to improve counseling and reduce anxiety, especially for those with a poor prognosis.
The trial randomly assigns 1126 women aged 18 to 44 undergoing their first IVF cycle with five or fewer embryos to either receive embryo transfer at the cleavage stage day 3, 8-cell embryo or at the blastocyst stage day 5-7 embryo. Surplus embryos that meet freezing criteria may be frozen and transferred in a later cycle. The study is conducted across nine IVF centers in the US.
Participants will be monitored for six months or until all embryos have been transferred, and if pregnancy occurs, follow-up continues until delivery. Researchers will assess the chance of live birth per cycle, risks of miscarriage, multiple pregnancies, and cycle cancellations, along with secondary measures such as time to pregnancy, number of procedures, adverse perinatal outcomes, financial burden, and patient satisfaction. The study also examines factors affecting patient involvement in embryo transfer timing and guideline implementation.
CONDITIONS
Brief Title
Cleavage-stage Versus Blastocyst-stage Embryo Transfer in IVF Patients With Few Embryos
Research Team
B
Beatrice Duvert
W
Werner Neuhausser, MD PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Blastocyst-stage Embryo Transfer
Cleavage-stage Embryo Transfer
What it is
Transfer of embryo(s) at the blastocyst stage (typically day 5–7 of development) after IVF, in a fresh IVF cycle.
Transfer of embryo(s) at the cleavage stage (typically day 2–3 of development) as part of the fresh IVF cycle.
Role in this trial
Patients are randomized to receive their embryo transfer at the blastocyst stage as an approach to maximize live birth rates with few embryos available.
Patients are randomized to receive their embryo transfer at the cleavage stage as an alternative established approach when few embryos are present.
Primary use
Used to potentially improve live birth rates and per-transfer implantation in IVF when only a limited number of embryos are available.
An established practice aiming to give every viable embryo a chance to implant early in development for patients with few embryos.
How it is given or performed
Embryos are cultured in the laboratory until the blastocyst stage (day 5–7) then transferred into the uterus in a fresh cycle.
Embryos are transferred into the uterus at the cleavage stage (day 2–3) post-fertilization in a fresh cycle.
Evidence status
Effectiveness for cumulative live birth and other outcomes in this precise IVF population is being directly compared as part of an ongoing randomized trial.
This approach is well established in practice and directly compared in the ongoing randomized trial to clarify its effectiveness when only a few embryos are present.
Important limitations
May risk having no embryos suitable for transfer if embryos do not survive to blastocyst stage, especially when only a few embryos exist.
Embryos are transferred earlier, so the selection for transfer is based on earlier development, which may lead to lower implantation rates in some cases.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years - 44Years
FEMALE
Eligibility Criteria
You may qualify if you...
Undergoing autologous IVF cycle
Have 5 or fewer zygotes on day 1 of embryo development
Planned fresh embryo transfer
You will not qualify if you...
Planned preimplantation genetic testing (PGT) of all embryos
More than 2 previous IVF cycles
History of recurrent pregnancy loss (3 or more losses)
Body mass index (BMI) greater than 40
Uterine factor infertility
Planned gestational carrier
Endometrial lining less than 6mm on trigger day
Use of Lupron-only trigger or elevated progesterone in fresh cycle (≥1.5 ng/ml)
Delayed fertilization (more than 18 hours)
Rescue intracytoplasmic sperm injection after failed fertilization
Use of non-ejaculated sperm (testicular sperm extraction)
Embryo transfer number outside ASRM guidelines
Cycle converted to all embryos frozen
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 6 months or until all embryos are transferred
Participants receive embryo transfer either at the cleavage stage (day 3) or blastocyst stage (day 5-7) as part of their IVF treatment.
Visits aligned with embryo transfer procedures and monitoring during IVF cycles
Follow-up
Duration - Up to 9 months after embryo transfer until delivery
Participants are monitored for pregnancy outcomes including live birth, multiple pregnancy, and other pregnancy-related assessments until delivery if pregnancy is achieved.
Approximately monthly visits or contacts during pregnancy
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Large Prospective Study on Environmental and Lifestyle Effects on Infertility and Assisted Reproductive Technology Success
Evaluating an AI-Driven Model to Improve Patient Engagement and Outcomes in Medically Assisted Reproduction for Infertility
Study of a Personalized Decision Support Tool to Optimize IVF Drug Dosage for Women with Infertility
Study of Telomere and Biological Aging Markers to Guide Personalized Traditional Chinese and Conventional Medicine Treatment in Women With Persistent Unexplained Infertility After Prior Treatments
Comparing Day 3 and Day 5 Embryo Transfer Timing in Women Undergoing IVF with Few Embryos
Developing an AI Tool to Analyze Sperm Samples and Predict Fertility Outcomes in IVF and ICSI Treatments
Using Artificial Intelligence to Predict Uterine Lining Readiness During In Vitro Fertilization in Women Aged 18 to 40
Study of Personalized Follitropin Delta Dosing with a Long GnRH Agonist Protocol in Women Undergoing IVF or ICSI
Effects of Growth Hormone and Dehydroepiandrosterone on Women with Poor Ovarian Reserve During In Vitro Fertilization
Study to Test the Safety and Effectiveness of Human Menopausal Gonadotropin Injections for Women with Infertility Undergoing Assisted Reproductive Technology to Improve Pregnancy and Live Birth Rates
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Multicentre randomised comparative effectiveness trial of cleavage-stage versus blastocyst-stage embryo transfer in patients with few embryos (PRECISE): implementation of a study protocol in reproductive medicine.
Werner M Neuhausser, Denis A Vaughan, Denny Sakkas...